Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.28 USD | +0.61% | -0.84% | +126.09% |
13/05 | Oppenheimer Adjusts Mind Medicine Price Target to $20 From $29, Maintains Outperform Rating | MT |
08/05 | Transcript : Mind Medicine Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+126.09% | 592M | |
+54.64% | 63.85B | |
-1.31% | 41.83B | |
+40.49% | 40.47B | |
-10.02% | 27.17B | |
+14.70% | 26.52B | |
-20.59% | 18.69B | |
+3.37% | 12.73B | |
+22.09% | 12.11B | |
+29.27% | 12.07B |
- Stock Market
- Equities
- MNMD Stock
- News Mind Medicine (MindMed) Inc.
- Oppenheimer Adjusts Mind Medicine Price Target to $20 From $29, Maintains Outperform Rating